CRVO NASDAQ
CervoMed Inc.
1W: -11.4%
1M: -26.6%
3M: -33.0%
YTD: -67.1%
1Y: -71.5%
3Y: -45.0%
5Y: -93.8%
$2.56
-0.10 (-3.76%)
Weekly Expected Move ±14.9%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$9.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$23.7M
52W Range2.13-11.25
Volume408,897
Avg Volume5,704,452
Beta-4.42
Dividend—
Analyst Ratings
Company Info
CEOJohn J. Alam
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2008-05-23
Websitecervomed.com
20 Park Plaza
Boston, MA 02116
US
Boston, MA 02116
US
617-744-4400
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodâbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Latest News
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
12 Health Care Stocks Moving In Thursday's Pre-Market Session
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BOGER JOSHUA S | P-Purchase | 955,414 | $3.14 | 2026-06-11 |
| BOGER JOSHUA S | P-Purchase | 955,414 | $3.32 | 2026-06-11 |
| BOGER JOSHUA S | P-Purchase | 955,414 | $3.14 | 2026-06-11 |
| Poulton Jeffrey V. | A-Award | 8,150 | $2.91 | 2026-06-08 |
| Hollingsworth Jane H | A-Award | 8,150 | $2.91 | 2026-06-08 |